Co-delivery of Paclitaxel and survivin shRNA nanoparticles lowered IC50 by 360-fold in Paclitaxel resistant lung cancer cells against A549/T cells compared to free Paclitaxel and enhanced efficacy with Paclitaxel induced apoptosis and cell arrest in G2/M phase. The gene discussed is BIRC5; the disease is lung cancer.